Abstract
Background: Frontotemporal Dementia (FTD) is a heterogeneous group of disorders and the second most frequent cause of early onset dementia making it the highest number of inherited cases.
Review Summary: FTD is characterized by considerable variability in clinical, genetic and histopathologic features. Patients may present symptoms ranging from behavioural disturbances to different language disorders, with or without motor neuron disorders or associated parkinsonism. Atrophy in frontal and temporal lobes is the most relevant radiological finding. In the last 10 years, the knowledge of this clinical entity has undergone remarkable changes both genetically and histopathologically, which have served to establish more consistent clinical criteria. Until now, 10 genes causative of FTLD have been described and up to four different proteins causative of atrophy have been detected in aggregates.
Conclusion: This review is mostly addressed to clinicians and aims to provide basic knowledge of these neurodegenerative disorders and clarify the complex FTD scenario.
Keywords: FTLD, phenotypes, proteotypes, genotypes, review, neurologist.
Current Alzheimer Research
Title:Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists
Volume: 15 Issue: 6
Author(s): Isabel Hernandez*, Maria-Victoria Fernandez, Lluis Tarraga, Merce Boada and Agustín Ruiz
Affiliation:
- Fundacio ACE, Memory Unit. Av Carlos III, 85 bis. Barcelona, ES 08028,Spain
Keywords: FTLD, phenotypes, proteotypes, genotypes, review, neurologist.
Abstract: Background: Frontotemporal Dementia (FTD) is a heterogeneous group of disorders and the second most frequent cause of early onset dementia making it the highest number of inherited cases.
Review Summary: FTD is characterized by considerable variability in clinical, genetic and histopathologic features. Patients may present symptoms ranging from behavioural disturbances to different language disorders, with or without motor neuron disorders or associated parkinsonism. Atrophy in frontal and temporal lobes is the most relevant radiological finding. In the last 10 years, the knowledge of this clinical entity has undergone remarkable changes both genetically and histopathologically, which have served to establish more consistent clinical criteria. Until now, 10 genes causative of FTLD have been described and up to four different proteins causative of atrophy have been detected in aggregates.
Conclusion: This review is mostly addressed to clinicians and aims to provide basic knowledge of these neurodegenerative disorders and clarify the complex FTD scenario.
Export Options
About this article
Cite this article as:
Hernandez Isabel *, Fernandez Maria-Victoria, Tarraga Lluis , Boada Merce and Ruiz Agustín , Frontotemporal Lobar Degeneration (FTLD): Review and Update for Clinical Neurologists, Current Alzheimer Research 2018; 15 (6) . https://dx.doi.org/10.2174/1567205014666170725130819
DOI https://dx.doi.org/10.2174/1567205014666170725130819 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Pilot Study of Exenatide Actions in Alzheimer’s Disease
Current Alzheimer Research Therapeutic Potential of Janus Kinase 3 (JAK3) Inhibitors
Current Pharmaceutical Design Inflammation, Oxidative Stress and Metabolic Syndrome: Dietary Modulation
Current Vascular Pharmacology Brain Slices as Models for Neurodegenerative Disease and Screening Platforms to Identify Novel Therapeutics
Current Neuropharmacology γ-Secretase as a Therapeutic Target for Treatment of Alzheimers Disease
Current Pharmaceutical Design Recent Advances in the Discovery of α1-Adrenoceptor Agonists
Current Topics in Medicinal Chemistry Editorial [ New Advances in Alzheimers Disease: From Biology to Therapy Guest Editor: Giuseppina Tesco ]
Current Genomics Docking-based 3D-QSAR Studies of Phosphodiesterase 9A Inhibitors
Letters in Drug Design & Discovery Insights into Aβ Aggregation: A Molecular Dynamics Perspective
Current Topics in Medicinal Chemistry Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry Military Risk Factors for Cognitive Decline, Dementia and Alzheimer’s Disease
Current Alzheimer Research Ageing as a Trait de Union Between Diabetes and Dementia for Frailty
CNS & Neurological Disorders - Drug Targets Opinion Paper: Post-surgical Delirium, Consciousness, and Therapy
Recent Patents on CNS Drug Discovery (Discontinued) Sleep and Antidepressant Treatment
Current Pharmaceutical Design Tuberculosis Infections of the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Amyloid Beta Protein and Tau in Cerebrospinal Fluid and Plasma as Biomarkers for Dementia: A Review of Recent Literature
Current Clinical Pharmacology Recent Advances in Transcranial Focused Ultrasound (FUS) Triggered Brain Delivery
Current Drug Targets Cerebral Collateral Circulation in Carotid Artery Disease
Current Cardiology Reviews Sialic Acid and the Central Nervous System: Perspectives on Biological Functions, Detection, Imaging Methods and Manipulation
CNS & Neurological Disorders - Drug Targets Neural and Behavioral Responses to Systemic Immunologic Stimuli: A Consideration of Bacterial T Cell Superantigens
Current Pharmaceutical Design